Physicians' Academy for Cardiovascular Education

GLP-1 analogue in T2DM leads to amylase and lipase elevations but not acute pancreatitis

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

Literature - Steinberg WM, Buse JB, Ghorbani MLM, et al; LEADER Steering Committee; LEADER Trial Investigators - Diabetes Care. 2017; published online ahead of print

Main results

Conclusion

In the LEADER study, numerically fewer events of acute pancreatitis were observed in the liraglutide group compared with the placebo group. Liraglutide increased serum amylase and lipase levels, but these elevations were not predictive of the development of acute pancreatitis in asymptomatic T2DM patients.

References

Show references

Find this article online at Diabetes Care

Share this page with your colleagues and friends: